NEUVIOR Pharmaceuticals has announced it has been awarded a feasibility grant from Innovate UK under its Resource Efficiency for Resilience and Sustainability competition.
This award is separate from the company's previous Innovate UK funding.
ZYLON, developed under an Innovate UK-funded feasibility project (VIONIX ZERO — Bio-Intelligent Materials for Net-Zero Pharmaceutical Manufacturing), supports early-stage work to explore how pharmaceutical production can become more circular, less wasteful and lower-carbon.
ZYLON is NEUVIOR's commercial programme focused on recovering material from pharmaceutical manufacturing processes and developing smarter, bio-based packaging materials that could replace harder-to-recycle formats.
The award represents an important feasibility-stage validation, providing an initial public proof point for the concept with future customers, partners and investors.
Varun Cruz, Founder of NEUVIOR, said: "ZYLON is about turning early-stage ideas into real, testable data."
This feasibility work allows us to validate core assumptions in a live lab environment and define a credible path toward more circular pharmaceutical manufacturing.
Following the award, NEUVIOR has progressed from a funded concept to early laboratory execution.
Clean chemistry feasibility trials are currently being conducted at the Biorenewables Development Centre in York, utilising their pilot-scale bioprocessing centre for technical support and testing.
Mark Gronnow, Process Development Team Lead at the Biorenewables Development Centre, added: "The BDC is happy to support NEUVIOR on their development journey of an exciting biobased product range."
Being able to rapidly and flexibly support innovators with facilities and resources is one of our specialisms.
These trials are focused on disciplined lab execution and the generation of baseline data, exploring bio-derived inputs and de-risking potential approaches that could underpin more circular pharmaceutical manufacturing systems and will be led by Dr Carlos Bueno Alejo.
Dr Carlos Bueno Alejo said: "I'm excited to participate in this interesting feasibility project that could have a great impact on how pharmaceutical products are manufactured in a more sustainable way."
The programme strengthens NEUVIOR's position in manufacturing innovation across pharmaceuticals, materials and sustainability, while enhancing its work in software and AI-driven platforms.
Currently, the company said, the focus is on feasibility studies, prototyping and early trials to guide future development and scaling.